Repligen Corporation (NASDAQ:RGEN) Shares Sold by Norden Group LLC

Norden Group LLC cut its position in shares of Repligen Corporation (NASDAQ:RGEN) by 31.1% in the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 2,549 shares of the biotechnology company’s stock after selling 1,149 shares during the quarter. Norden Group LLC’s holdings in Repligen were worth $324,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Price T Rowe Associates Inc. MD grew its stake in shares of Repligen by 11.6% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 7,136,054 shares of the biotechnology company’s stock valued at $1,027,165,000 after buying an additional 743,815 shares in the last quarter. Champlain Investment Partners LLC grew its stake in Repligen by 8.6% during the 4th quarter. Champlain Investment Partners LLC now owns 1,543,530 shares of the biotechnology company’s stock valued at $222,176,000 after purchasing an additional 122,595 shares in the last quarter. Alliancebernstein L.P. increased its holdings in Repligen by 23.4% during the 4th quarter. Alliancebernstein L.P. now owns 1,010,896 shares of the biotechnology company’s stock worth $145,508,000 after purchasing an additional 191,439 shares during the last quarter. Conestoga Capital Advisors LLC increased its holdings in Repligen by 3.4% during the 1st quarter. Conestoga Capital Advisors LLC now owns 980,247 shares of the biotechnology company’s stock worth $124,727,000 after purchasing an additional 32,665 shares during the last quarter. Finally, Point72 Asset Management L.P. increased its holdings in Repligen by 183.1% during the 4th quarter. Point72 Asset Management L.P. now owns 918,623 shares of the biotechnology company’s stock worth $132,227,000 after purchasing an additional 594,189 shares during the last quarter. 97.64% of the stock is currently owned by institutional investors and hedge funds.

Repligen Price Performance

Shares of RGEN opened at $122.85 on Thursday. The company has a market cap of $6.90 billion, a P/E ratio of -491.38, a PEG ratio of 2.32 and a beta of 1.11. The stock has a fifty day moving average price of $123.46 and a 200 day moving average price of $136.78. The company has a debt-to-equity ratio of 0.27, a current ratio of 6.79 and a quick ratio of 5.79. Repligen Corporation has a 12 month low of $102.96 and a 12 month high of $182.52.

Repligen (NASDAQ:RGEN) last issued its quarterly earnings data on Tuesday, July 29th. The biotechnology company reported $0.37 EPS for the quarter, missing analysts’ consensus estimates of $0.40 by ($0.03). The company had revenue of $182.37 million for the quarter, compared to the consensus estimate of $174.62 million. Repligen had a positive return on equity of 4.65% and a negative net margin of 2.05%. Repligen’s quarterly revenue was up 14.8% compared to the same quarter last year. During the same quarter in the previous year, the company earned $0.40 earnings per share. On average, research analysts forecast that Repligen Corporation will post 1.72 earnings per share for the current year.

Analyst Upgrades and Downgrades

RGEN has been the topic of several analyst reports. Stephens upgraded Repligen to an “overweight” rating and set a $160.00 price objective on the stock in a report on Tuesday, July 22nd. JPMorgan Chase & Co. dropped their price objective on Repligen from $200.00 to $190.00 and set an “overweight” rating on the stock in a report on Tuesday, April 29th. HC Wainwright restated a “buy” rating and set a $180.00 price objective on shares of Repligen in a report on Monday, May 5th. Barclays assumed coverage on Repligen in a report on Tuesday, June 24th. They set an “overweight” rating and a $150.00 price objective on the stock. Finally, Wall Street Zen lowered Repligen from a “buy” rating to a “hold” rating in a research report on Sunday, June 29th. Five investment analysts have rated the stock with a hold rating and nine have assigned a buy rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $170.75.

About Repligen

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.